Advancing tumor vaccines: Overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy

Tumor vaccines, as an immunotherapeutic approach, harness the body's immune cells to provoke antitumor responses, which have shown promising efficacy in clinical settings. However, the immunosuppressive tumor microenvironment (TME) and the ineffective vaccine delivery systems hinder the progres...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2025-01, Vol.205, p.104576, Article 104576
Main Authors: Zeng, Qingsong, Zhang, Shibo, Leng, Ning, Xing, Yingying
Format: Article
Language:English
Subjects:
Animals
Biocompatible Materials
Biomaterial-Based Vaccine
Cancer Vaccines - administration & dosage
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
Drug Delivery Systems - methods
Humans
Immunotherapy - methods
Neoplasms - immunology
Neoplasms - therapy
Tumor Microenvironment
Tumor Microenvironment - immunology
Tumor Vaccines
Vaccine Delivery Systems
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor vaccines, as an immunotherapeutic approach, harness the body's immune cells to provoke antitumor responses, which have shown promising efficacy in clinical settings. However, the immunosuppressive tumor microenvironment (TME) and the ineffective vaccine delivery systems hinder the progression of many vaccines beyond phase II trials. This article begins with a comprehensive review of the complex interactions between tumor vaccines and TME, summarizing the current state of vaccine clinical research. Subsequently, we review recent advancements in targeted vaccine delivery systems and explore biomaterial-based tumor vaccines as a strategy to improve the efficacy of both delivery systems and treatment. Finally, we have presented our perspectives on tumor vaccine development, aiming to advance the field towards the creation of more effective tumor vaccines. [Display omitted] •Tumor vaccines represent a promising new frontier in cancer immunotherapy.•Vaccine delivery systems enhance the immunogenic effectiveness of vaccines.•Biomaterial-based vaccines contribute to the enhancement of therapeutic efficacy.
ISSN:1040-8428
1879-0461
1879-0461
DOI:10.1016/j.critrevonc.2024.104576